ELISA F29 –A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment

por Rivero, Rocio, Esteva, Mónica Inés, Huang, Erya, Colmegna, Leylen, Altcheh, Jaime, Grossmann, Ulrike, Ruiz, Andrés Mariano
Publicado 2023

Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina

por Vizcaya, David, Grossmann, Ulrike, Kleinjung, Frank, Zhang, Ruiping, Suzart-Woischnik, Kiliana, Seu, Sandra, Ramirez, Teresa, Colmegna, Leylen, Ledesma, Oscar
Publicado 2021